A multicenter team including Endeavor Health and Eli Lilly found that once-weekly eloralintide produced dose-dependent weight loss up to 20% over 48 weeks in adults with obesity or overweight without type 2 diabetes.
Once-weekly eloralintide leads to 20% weight loss in Phase II trial
